LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

47.567

105.69

EPS

0.4

Dividendrendement

0.31

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+19.81% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.31%

2.37%

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-815M

10B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

32%

68%

91 / 374 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 nov 2025, 18:59 UTC

Belangrijke Marktbewegers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Marktinformatie

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Marktinformatie

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Marktinformatie

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Winsten

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Winsten

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Marktinformatie

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Marktinformatie

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Acquisities, Fusies, Overnames

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Winsten

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Acquisities, Fusies, Overnames

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Marktinformatie

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

19.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.1 USD  19.81%

Hoogste 125 USD

Laagste 100 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Sentiment

By Acuity

91 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat